Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

Author:

El-Osta Hazem E.1,Kurzrock Razelle1

Affiliation:

1. Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

Abstract

Abstract Castleman's disease is a rare lymphoproliferative disorder in which there has been recent progress in elucidating underlying mechanisms with potential therapeutic implications. Unicentric Castleman's disease is an indolent condition that is often treated with local approaches. In contrast, patients with multicentric Castleman's disease (MCD) have a less favorable prognosis and require systemic treatment. Cytotoxic chemotherapy, with its attendant risk for toxicity, has been widely used to treat MCD, with variable efficacy. The discovery of putative etiologic factors and targets in MCD, particularly human herpes virus 8, CD20, and interleukin (IL)-6, has been translated into the use of rituximab and anti–IL-6-based therapy, as well as antiviral agents. In this article, we review the current state of the art of our understanding of Castleman's disease and its treatment and we provide insight into future treatment strategies based on disease biology.

Funder

National Center for Research Resources

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference109 articles.

1. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot;Castleman;N Engl J Med,1954

2. The aetiology and management of Castleman disease at 50 years: Translating pathophysiology to patient care;Casper;Br J Haematol,2005

3. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma;Dupin;Blood,2000

4. Castleman disease;Dham;Curr Opin Hematol,2007

5. [Castleman's disease];Larroche;Rev Med Interne,1996

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3